View Financial HealthBicycle Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Bicycle Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.01%자사주 매입 수익률총 주주 수익률-0.01%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBicycle Therapeutics plc Provides Update on Nuzefatide Pevedotin and EphA2 PipelineApr 20Bicycle Therapeutics plc, Annual General Meeting, Jun 17, 2026Apr 06Full year 2025 earnings: EPS and revenues exceed analyst expectations Mar 18Bicycle Therapeutics plc Announces Executive Changes, Effective March 12, 2026Mar 17Price target decreased by 13% to US$18.80 Feb 17We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth CarefullyFeb 05Bicycle Therapeutics plc Announces Executive ChangesFeb 03+ 1 more updateCEO & Executive Director recently sold US$141k worth of stock Jan 09Price target decreased by 11% to US$21.28 Nov 03Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Nov 02Consensus revenue estimates increase by 10% Oct 31Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn Oct 15Bicycle Therapeutics plc Announces Board AppointmentsSep 09Analysts Just Slashed Their Bicycle Therapeutics plc (NASDAQ:BCYC) EPS NumbersAug 18High number of new and inexperienced directors Aug 14Analysts Have Lowered Expectations For Bicycle Therapeutics plc (NASDAQ:BCYC) After Its Latest ResultsAug 13Second quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 10Bicycle Therapeutics plc Announces Board and Executive AppointmentsAug 08Is Bicycle Therapeutics (NASDAQ:BCYC) In A Good Position To Deliver On Growth Plans?Jun 18First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind May 04Price target decreased by 10% to US$24.90 May 02Bicycle Therapeutics plc Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025Apr 29Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted Apr 22Bicycle Therapeutics plc Announces Management ChangesMar 27Bicycle Therapeutics plc, Annual General Meeting, Jun 17, 2025Mar 17Price target decreased by 7.9% to US$29.55 Feb 26Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 26AI Proteins, Inc. Appoints Philip E. Brandish, PhD as Chief Development OfficerFeb 12Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data Feb 02Bicycle Therapeutics plc Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and MilestonesJan 13We're Not Very Worried About Bicycle Therapeutics' (NASDAQ:BCYC) Cash Burn RateJan 06New major risk - Revenue and earnings growth Dec 16Price target decreased by 7.0% to US$36.45 Dec 13Bicycle Therapeutics plc Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene AmplificationDec 13Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsDec 10Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern Nov 07Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearNov 03Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 01New major risk - Revenue and earnings growth Nov 01Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 CongressOct 23Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, AnywayOct 23Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline At ESMO Congress 2024Sep 14New minor risk - Share price stability Sep 10Bicycle Therapeutics Is Looking Increasingly Attractive Aug 20Consensus estimates of losses per share improve by 29% Aug 13Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 07New major risk - Shareholder dilution Jun 02Bicycle Therapeutics plc announced that it expects to receive $555.499983 million in funding from Deep Track Capital, LP, EcoR1 Capital, LLC, Perceptive Advisors LLC, RA Capital Management, L.P.May 24Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert May 24Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingMay 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's WhyMay 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging HigherMay 04New major risk - Revenue and earnings growth May 03First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 03Bicycle Therapeutics plc Announces Promotion of Mike Hannay as Chief Product and Supply Chain OfficerMay 03Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?Apr 19Bicycle Therapeutics plc Announces Board ChangesApr 19Bicycle Therapeutics plc, Annual General Meeting, May 16, 2024Apr 16Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point Mar 12Consensus revenue estimates decrease by 12%, EPS upgraded Feb 21Bicycle Therapeutics Appoints Stephen Sands to the Board of DirectorsFeb 21New minor risk - Share price stability Feb 14CEO & Executive Director notifies of intention to sell stock Jan 06CEO & Executive Director notifies of intention to sell stock Jan 06Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt SafelyJan 04Price target decreased by 9.1% to US$44.47 Dec 20Bicycle Therapeutics Provides Clinical Updates for BT8009, BT7480 and BT5528Dec 15Consensus revenue estimates fall by 22% Nov 09Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue ForecastsNov 07Third quarter 2023 earnings released: US$1.26 loss per share (vs US$0.95 loss in 3Q 2022) Nov 03Insufficient new directors Nov 01Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder CancerSep 12Consensus revenue estimates increase by 29%, EPS downgraded Aug 10Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 04New minor risk - Shareholder dilution Jul 15Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer, Effective July 17, 2023Jun 24+ 1 more updateThe Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales ForecastsMay 14Consensus revenue estimates increase by 52%, EPS downgraded May 11First quarter 2023 earnings: EPS and revenues miss analyst expectations May 06Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%Mar 31Consensus revenue estimates increase by 26% Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?Mar 09Full year 2022 earnings released: US$3.80 loss per share (vs US$2.67 loss in FY 2021) Mar 01Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of Bt8009Feb 15Bicycle Therapeutics plc Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial CancerJan 05Consensus revenue estimates fall by 19% Nov 16Consensus revenue estimates fall by 19% Nov 10Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) OutlookNov 08Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 04Bicycle Therapeutics: Exploring An Intriguing Developmental Platform Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform Aug 31Consensus forecasts updated Aug 11Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 05High number of new directors Aug 04Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration Jul 12지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BCYC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BCYC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Bicycle Therapeutics 배당 수익률 vs 시장BCYC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BCYC)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.6%분석가 예측 (BCYC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BCYC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BCYC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BCYC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BCYC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 09:28종가2026/05/01 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bicycle Therapeutics plc는 22명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kalpit PatelB. Riley Securities, Inc.Arlinda LeeCanaccord GenuityLi Wang WatsekCantor Fitzgerald & Co.19명의 분석가 더 보기
Analysts Have Lowered Expectations For Bicycle Therapeutics plc (NASDAQ:BCYC) After Its Latest ResultsAug 13
Bicycle Therapeutics plc Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025Apr 29
Bicycle Therapeutics plc Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and MilestonesJan 13
Bicycle Therapeutics plc Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging Nectin4 Gene AmplificationDec 13
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsDec 10
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearNov 03
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 CongressOct 23
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, AnywayOct 23
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline At ESMO Congress 2024Sep 14
Bicycle Therapeutics plc announced that it expects to receive $555.499983 million in funding from Deep Track Capital, LP, EcoR1 Capital, LLC, Perceptive Advisors LLC, RA Capital Management, L.P.May 24
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual MeetingMay 24
Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's WhyMay 10
Bicycle Therapeutics plc Announces Promotion of Mike Hannay as Chief Product and Supply Chain OfficerMay 03
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue ForecastsNov 07
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder CancerSep 12
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer, Effective July 17, 2023Jun 24+ 1 more update
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%Mar 31
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of Bt8009Feb 15
Bicycle Therapeutics plc Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial CancerJan 05